NONOF News and Press, Novo Nordisk - Class B From 02/24/26

2026-02-24 14:30:38 ET Intro I think everyone agrees that things have been genuinely tough for Hims & Hers Health, Inc. ( HIMS ), and its shareholders lately— the stock is down more than 75% after touching all‑time highs above $60 as recently as last October. I...

2026-02-24 12:50:19 ET More on Novo Nordisk A/S Novo Nordisk: Investors Focusing On CagriSema Results Are Missing The Big Picture Novo Nordisk: Redefine 4 Misses The Mark Novo Nordisk: Why Wegovy Growth Beats Wall Street Expectations Novo’s China obesi...

2026-02-24 09:00:00 ET Novo Nordisk A/S ( NVO ), listed in its home market as NOVO-B.CO, brought out a press release on February 23rd concerning results from its latest phase 3 trial for CagriSema. This is the company’s next-generation injectable weight loss drug, which c...

2026-02-24 08:47:21 ET Investment Thesis Hims & Hers Health ( HIMS ) has clearly moved from a valuation reset to a regulatory repricing event. HIMS over the past year has gone through a severe valuation reset, losing another 48% from my last coverage . However, the recen...

2026-02-19 09:02:43 ET Three months ago, in November 2025, an article about Novo Nordisk (NVO) argued that the stock was presenting a rare second chance, with the stock declining to about DKK 300. In the meantime, the stock increased and performed quite well, but since the end of Ja...

2026-02-18 16:51:24 ET Intro I think it's good to start with taking the line from my last piece, which, to me, describes Structure Therapeutics Inc. ( GPCR ) as a business really well: It is a GLP‑1 oral pure play trying to access one of today’s largest and faste...

2026-02-18 11:30:00 ET Whenever I think about the thesis for Pfizer Inc. ( PFE ), I can't help but ruminate over why the market has not shown much conviction despite PFE trading at valuations that are still undisputably close to the 10-year lows in PFE's history. While I'm not a Pfi...

2026-02-18 09:06:40 ET Investment Overview: A Quick History Of Hims & Hers' Attempts To Sell Compounded GLP-1 Drugs Read the full article on Seeking Alpha For further details see: Hims & Hers Health: 5 Key Questions Ahead Of Critical Q4 Earnings

2026-02-17 12:36:58 ET My last article in November 2025 on the obesity treatments' provider Novo Nordisk A/S's ( NVO ) was titled “ Consider The Counterfactual .” The title followed a sharp fall in its stock price after it released disappointing financials, which I...

2026-02-17 10:00:45 ET More on Novo Nordisk Novo Nordisk: How Low Is Too Low? (Downgrade, Technical Analysis) Novo Nordisk: Ugly Guidance, But Stock Refuses To Break Down Further Novo Nordisk: Full Kitchen Sink Reset Or Another Shoe Yet To Drop? Novo Nordisk ...